SCHEMBL462907

SCHEMBL462907

Cc1n[nH]c2cccc(-c3cnc4ccccc4c3)c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRA P16234 4/20 0.51
▸ PDGFRB P09619 3/20 0.51
▸ CYP1A2 P05177 1/20 0.43
▸ PARP10 Q53GL7 1/20 0.43
▸ PARP11 Q9NR21 1/20 0.43
▸ BIRC5 O15392 1/20 0.43
▸ BRD4 O60885 2/20 0.42
▸ CREBBP Q92793 2/20 0.42
▸ LRRK2 Q5S007 1/20 0.42
▸ MAP4K4 O95819 1/20 0.41
▸ CSNK1G2 P78368 1/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ MKNK2 Q9HBH9 1/20 0.41
▸ MAP4K5 Q9Y4K4 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ PIM3 Q86V86 1/20 0.41
▸ PIM2 Q9P1W9 1/20 0.41
▸ KIT P10721 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ CYP2A6 P11509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL462976 0.84 PDGFRB (0.51) PDGFRAPDGFRBPARP10PARP11BIRC5
SCHEMBL461745 0.84 PDGFRB (0.51) PDGFRAPDGFRBPARP10PARP11BIRC5
SCHEMBL462861 0.81 PDGFRB (0.48) PDGFRAPDGFRBBIRC5BRD4CREBBP
SCHEMBL2695137 0.81 PDGFRA (0.49) PDGFRAPDGFRBCYP1A2PARP10PARP11
SCHEMBL1042969 0.79 PDGFRA (0.51) PDGFRAPDGFRBCYP1A2PARP10PARP11
SCHEMBL1045276 0.79 PDGFRB (0.61) PDGFRAPDGFRBCYP1A2PARP10PARP11
SCHEMBL2182815 0.76 PDGFRB (0.60) PDGFRAPDGFRBCYP1A2BIRC5BRD4
SCHEMBL1045337 0.75 PDGFRB (0.56) PDGFRAPDGFRBCYP1A2PARP10PARP11
SCHEMBL17179205 0.75 PIM1 (0.60) PDGFRAPDGFRBBIRC5LRRK2PIM1
SCHEMBL1394258 0.74 METAP2 (0.60) PDGFRAPDGFRBBIRC5BRD4CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408762-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-25 — — EP disclosed
US-20120010241-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-12 — — US disclosed
WO-2010106290-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2010-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010241-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF HSP90AB2P, HSP90AB1, HSP90AA1 PDGFRA 1508/4885PDGFRB 1416/4885CYP1A2 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback